Science AI Journal
Medicine · Research topic

Open research questions in Monoclonal and Polyclonal Antibodies Research

34 unresolved questions extracted from the limitations and future-work sections of 263 Monoclonal and Polyclonal Antibodies Research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Previous reports on the FCRL5-IgG interaction vary widely in reported affinities, binding differences across IgG subclasses, and molecular requirements for maximal binding.

    FCRL5 is a fucose-sensitive IgG-Fc receptor with binding properties distinct from classical Fcγ receptors · 2026 · DOI

  • CD4+ T cells coordinate immune responses to infections and cancers and initiate many autoimmune diseases, yet the intracellular pathways that generate the peptide antigens they recognize remain incompletely understood.

    Generation and MHC class II loading of an endogenous influenza epitope revealed by a T cell receptor-like antibody · 2026 · DOI

  • Tumour necrosis factor receptor superfamily (TNFRSF)-targeting bispecific antibodies (bsAb) enable tumour-localised T cell co-stimulation, yet how antibody architecture and receptor choice govern activity remains unclear.

    Bispecific Antibody Architecture and TNFRSF Target Selection Determine CD8+ T Cell Differentiation and Anti-tumour Immunity · 2026 · DOI

  • The mechanical response of the interaction between the T cell receptor (TCR) and the peptide major histocompatibility complex (pMHC) is fundamental to antigen recognition, but the atomic-scale mechanisms by which the CD8 coreceptor modulates the complex's conformational states and force-bearing behavior remain poorly understood.

    CD8-mediated organization of the TCR-pMHC interface shapes its force response and dissociation pathways · 2026 · DOI

  • The molecular determinants governing Fc-Fc{gamma}R engagement in mice remain poorly defined, complicating the interpretation of murine ADCC data and its clinical relevance.

    Mouse Fc-FcγRIV structure guides Fc engineering for cross-species FcγR recognition · 2026 · DOI

  • The neutralizing activity of anti-drug antibodies (ADAs), especially neutralizing ADAs (nADAs) activity, should be examined considering that it can alter pharmacokinetic (PK) and pharmacodynamic (PD) profiles, reduce drug efficacy, and lead to life-threatening adverse events.

    Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa · 2026 · DOI

  • ARTIFICIAL INTELLIGENCE IN ANTIBODY DESIGN Artificial intelligence (AI) is transforming the field of antibody design by facilitating quick, precise, and economical predictions of antibody structures, binding affinities, and profiles for developability. Machine learning (ML) techniques, especially deep learning models like AlphaFold2 and those for protein-ligand in-silico generation and interactions, enable refinement of antibody candidates that exhibit both high specificity and low immunogenicity. AIbased tools combine extensive datasets from phage display, single-cell sequencing, and structural biology to forecast the conformations of complementaritydetermining regions (CDRs), detect possible off-target impacts, and modify Fc or glycan components for enhanced pharmacokinetics. In addition, generative AI methodologies can create completely new antibodies that extend beyond natural repertoires, thereby speeding up the process from hit identification to lead optimization. When paired with cloud-based solutions, AI systems are increasingly utilized screenings, multi-objective optimizations (considering binding, stability, and solubility), and directing experimental validation, thus changing conventional trial-and-error methods into predictive, the data-informed workflows development of antibody therapeutics.

    From Monoclonal to Multifunctional: The Evolving Landscape of Engineered Antibodies · 2026 · DOI

  • Inherent limitations are associated with the antibody characterization platform used in this study. Firstly, the YCharOS project focuses on renewable (recombinant and monoclonal) antibodies and does not test all commercially available CTHRC1 antibodies. YCharOS partners provide approximately 80% of all renewable antibodies, but some top-cited polyclonal antibodies may not be available through these partners. We encourage readers to consult vendor documentation to identify the specific antigen each antibody is raised against, where such information is available. Secondly, the YCharOS effort employs a non-biased approach that is agnostic to the protein for which antibodies have been characterized. The aim is to provide objective data on antibody performance without preconceived notions about how antibodies should perform or the molecular weight that should be observed in western blot. As the authors are not experts in CTHRC1, only a brief overview of the protein's function and its relevance in disease is provided. CTHRC1 experts are invited to analyze and interpret observed banding patterns in western blots. Thirdly, YCharOS experiments are not performed in replicates primarily due to the use of multiple antibodies targeting various epitopes. Once a specific antibody is identified, it validates the protein expression of the intended target in the selected cell line, confirms the lack of protein expression in the KO cell line and supports conclusions regarding the specificity of the other antibodies. All experiments are performed using master mixes, and meticulous attention is paid to sample preparation and experimental execution. In IF, the use of two different concentrations serves to evaluate antibody specificity and can aid in assessing assay reliability. In instances where antibodies yield no signal, a repeat experiment is conducted following titration. Additionally, our independent data is performed subsequently to the antibody manufacturers internal validation process, therefore making our characterization process a repeat. Lastly, as comprehensive and standardized procedures are respected, any conclusions remain confined to the experimental conditions and cell line used for this study. The use of a single cell type for evaluating antibody performance poses as a limitation, as factors such as target protein abundance significantly impact results. Additionally, the use of cancer cell lines containing gene mutations poses a potential challenge, as these mutations may be within the epitope coding sequence or other regions of the gene responsible for the intended target. Such alterations can impact the binding affinity of antibodies. This represents an inherent limitation of any approach that employs cancer cell lines.

    A guide to selecting high-performing antibodies for CTHRC1 (Q96CG8) for use in western blot and immunoprecipitation · 2026 · DOI

  • Inherent limitations are associated with the antibody characterization platform used in this study. First, the YCharOS project focuses on renewable (recombinant and monoclonal) antibodies and does not test all available antibodies against any given targets. While YCharOS partners provide access to the majority of renewable antibodies, some widely used polyclonal antibodies may not be included. Second, the YCharOS approach is protein-agnostic and aims to provide objective data on antibody performance without predefined expectations regarding molecular weight or localization. As such, only a brief overview of the protein target is provided, and expert interpretation of banding patterns and subcellular localization is encouraged. Third, experiments are not performed in biological replicates due to the parallel testing of multiple antibodies recognizing distinct epitopes. The identification of at least one specific antibody supports target expression in WT cells and its absence in KO cells, providing a reference for evaluating other antibodies. Experiments are performed using standardized conditions and master mixes to minimize variability.

    A guide to selecting high-performing renewable antibodies for KIF5A (Q12840) across western blot, immunoprecipitation, and immunofluorescence · 2026 · DOI

  • This study has several limitations. First, the included studies were mainly single-arm phase I/II clinical trials and retrospective real-world cohorts. No randomized controlled studies were avail- able. Therefore, we could not directly compare efficacy or safety across different BsAbs, or between BsAbs and CAR-T-cell therapy. Second, although we discussed our findings in the context of CAR-T studies such as ide-cel and cilta-cel, this comparison was indirect and contextual. It was affected by differences in eligibility criteria, number of prior lines of therapy, BCMA exposure status, follow-up duration, and endpoint assessment. Therefore, these data cannot support causal conclusions about whether CAR-T therapy is supe- rior or inferior to BsAbs. Third, the included studies differed in drug target, drug family, dosing regimen, step-up dosing strategy, CRS management, infec- tion prophylaxis, intravenous immunoglobulin (IVIG) use, and follow-up duration. These differences contributed to substantial heterogeneity in several outcomes. Fourth, real-world studies and clinical trials differed in performance status, comorbidities, tumor burden, prior treatment exposure, and completeness of response assessment. These differences may have affected the pooled esti- mates. Fifth, some outcomes were based on a limited number of cohorts, especially sCR, PFS, and grade ≥3 thrombocytopenia. This limited the precision of these estimates. Sixth, this review was not prospectively registered before study screening and data extraction. This may reduce methodological transparency and increase the risk of selective reporting. In addi- tion, ClinicalTrials.gov and other trial registries were not system- atically searched as independent sources, which may have led to omission of unpublished or ongoing studies. To mitigate these limitations, we provided the full search strategy, detailed data extraction tables, sensitivity analyses, meta-regression, subgroup analyses, publication-bias assessments, and GRADE certainty-of- evidence assessment. Seventh, although the MINORS assessment showed that the overall methodological quality of the included studies was moderate to high, most studies were still single-arm, open-label clinical trials or retrospective real-world cohorts. They lacked randomized control groups and may still be affected by selection bias, information bias, and residual confounding. The GRADE assessment also showed that the certainty of evidence for most major outcomes was low to very low. Therefore, our findings should be interpreted with caution. Future head-to-head compar- ative studies, randomized controlled trials, and long-term real- world studies are needed.

    Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies · 2026 · DOI

  • The study did not explore higher concentrations of arginine beyond 400 mM or alternative concentration ranges to determine if further improvements in recovery yield are possible.

    Investigation of the Effect of Arginine and Glutathione on Recovery of a Single Domain Antibody Produced in Bacteria in Inclusion Bodies · 2026 · DOI

  • The synergistic effect between arginine and GSH:GSSG was not observed due to the presence of 10 mM 2-ME in buffers; investigation of refolding conditions without 2-ME could reveal potential synergistic interactions.

    Investigation of the Effect of Arginine and Glutathione on Recovery of a Single Domain Antibody Produced in Bacteria in Inclusion Bodies · 2026 · DOI

  • The study investigated only a single HIV-1 capsid-binding nanobody; applicability to other antibody fragments with different structural features remains unexplored.

    Investigation of the Effect of Arginine and Glutathione on Recovery of a Single Domain Antibody Produced in Bacteria in Inclusion Bodies · 2026 · DOI

  • Because the diffusion of conventional antibodies in tissues is limited by their large size (150 kDa), it is necessary to find an antibody fragment that can cross the BBB and treat CNS infections.

    Complementarity-Determining Region 3 (CDR3) of the Heavy Chain Only Antibodies: Therapeutic Perspectives · 2024 · DOI

  • BsADCs, embodying a “1 þ 1” model, represent a novel therapeutic class that amalgamates the strengths of ADCs and BsAbs. This fusion leverages the anti-tumor mechanisms of ADCs, while addressing clinical challenges traditionally associated with ADCs through the versatility of BsAbs. BsADCs present a promising avenue for significantly enhancing the therapeutic efficacy of traditional ADCs, transcending conventional target and scaffold paradigms. Recent advancements have propelled BsADCs into phase I/II clinical trials, marking substantial progress in their development. Nevertheless, challenges persist, primarily attributed to the complexity of solid tumors, encompassing factors, compartmental heterogeneity, histological disorder, and poor penetration. It is imperative to refine the design strategy of BsADCs to overcome these challenges. In this review, we encapsulate the latest design considerations and advances in BsADCs, with the goal of charting a course for future drug design. While existing progress is noteworthy, the continued development and application of BsADCs face unique challenges in the following aspects. 4.1.

    Bispecific antibody drug conjugates: Making 1+1>2 · 2024 · DOI

  • The mechanism of all rituximab antitumor activity has not been established, but ADCC and CDC are believed to be the principal, with possible complementary effects.

    Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases · 2009 · DOI

  • However, the binding stoichiometries and interaction dynamics of ivonescimab with VEGF and PD-1 have not been characterized in depth.

    Mass photometry reveals stoichiometry and binding dynamics of bispecific tetravalent anti-VEGF-PD-1 antibody ivonescimab · 2026 · DOI

  • Third-generation approaches aim to preserve controlled conjugation while reducing sequence-engineering requirements, yet remain limited by a restricted number of accessible sites and less extensive clinical and regulatory experience.

    ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework · 2026 · DOI

  • These results show that systematic autoresearch can turn simple structural-confidence signals into compact, interpretable filters that are useful when target-specific training data are scarce.

    Autoresearch Discovery of Interpretable Filter Rules for Antibody Binder Classification · 2026 · DOI

  • Future work combining YTE with novel Fc modifications and delivery platforms promises to extend its impact across diverse therapeutic landscapes.

    YTE-engineered antibodies: From neonatal Fc receptor binding mechanisms to next-generation therapeutics · 2026 · DOI

  • The platform's capabilities are inherently dependent on the quality and scope of the integrated tools, and the agent cannot transcend the intrinsic limitations of underlying algorithms.

    ProteinMCP: An Agentic AI Framework for Autonomous Protein Engineering · 2026 · DOI

Most-cited papers in Monoclonal and Polyclonal Antibodies Research

Most recent work

Find a gap in your own Monoclonal and Polyclonal Antibodies Research sub-topic

This page shows what the Monoclonal and Polyclonal Antibodies Research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
34 open questions have been extracted from the limitations and future-work passages of 263 Monoclonal and Polyclonal Antibodies Research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.